ICAAC Conclave This Week Hosts 13,000 Microbiology Adepts

A virtual army of scientists dedicated to battling microscopic ene- mies is converging on Houston this week for the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. More than 13,000 microbiologists, clinicians, biochemists. pathologists, pharmacologists, and other scientists are expected to attend the conference, which opened yesterday, sponsored by the American Society for Microbiology (ASM). Researchers will present 1,365 short papers in 113 oral and poster sessions

Written byAngelo Martello
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A virtual army of scientists dedicated to battling microscopic ene- mies is converging on Houston this week for the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy.

More than 13,000 microbiologists, clinicians, biochemists. pathologists, pharmacologists, and other scientists are expected to attend the conference, which opened yesterday, sponsored by the American Society for Microbiology (ASM). Researchers will present 1,365 short papers in 113 oral and poster sessions. In addition to these sessions, there will be 17 special topics symposia.

More than 50 new compounds will be introduced this week through clinical or postclinical trial reports. The new compounds include chemotherapeutic, antifungal, antiviral, antibacterial, and anticancer agents.

Of these, the antiviral and anti-fungal agents appear to be commandeering more research than antibacterial agents. “The antibacterial area seems to be waning, whereas the antiviral and antifungal agents seem to be increasing,” says Robert L. Hamill, chairman of AS M’s Program and Planning ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies